TY - JOUR
T1 - Insights into gene therapy for critical limb ischemia
T2 - The devil is in the details
AU - Madonna, Rosalinda
AU - Rokosh, Gregg
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health, National Heart Lung and Blood Institute RO1 HL091202 and HL074351 (to G. Rokosh).
PY - 2012/8/19
Y1 - 2012/8/19
N2 - Patients with critical limb ischemia (CLI) without potential for revascularization are currently without alternate therapies. Several gene therapy trials have tested angiogenesis factors, hepatic growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, in rescuing CLI patients from amputation and mortality, and for improved quality of life including decreased pain, improved healing, and blood flow. Trial results have been variable, with HGF gene therapy being the most successful. New studies examining each of these angiogenic factors provide insights that will be useful for the design of effective therapeutic strategies.
AB - Patients with critical limb ischemia (CLI) without potential for revascularization are currently without alternate therapies. Several gene therapy trials have tested angiogenesis factors, hepatic growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, in rescuing CLI patients from amputation and mortality, and for improved quality of life including decreased pain, improved healing, and blood flow. Trial results have been variable, with HGF gene therapy being the most successful. New studies examining each of these angiogenic factors provide insights that will be useful for the design of effective therapeutic strategies.
KW - Basic fibroblast growth factor
KW - Critical limb ischemia
KW - Gene therapy
KW - Hepatocyte growth factor
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84862540404&partnerID=8YFLogxK
U2 - 10.1016/j.vph.2012.05.001
DO - 10.1016/j.vph.2012.05.001
M3 - Review article
C2 - 22580542
AN - SCOPUS:84862540404
SN - 1537-1891
VL - 57
SP - 10
EP - 14
JO - Vascular Pharmacology
JF - Vascular Pharmacology
IS - 1
ER -